MGMT Methylation and Differential Survival Impact by Sex in Glioblastoma

Addison E. Barnett,Ahmad Ozair,Anas S. Bamashmos,Hong Li,David S. Bosler,Gabrielle Yeaney,Assad Ali,David M. Peereboom,Justin D. Lathia,Manmeet S. Ahluwalia

DOI: https://doi.org/10.3390/cancers16071374

2024-04-01

Cancers

Abstract:Introduction: Sex differences in glioblastoma (GBM) have been observed in incidence, genetic and epigenetic alterations, and immune response. These differences have extended to the methylation of the MGMT promoter, which critically impacts temozolomide resistance. However, the association between sex, MGMT methylation, and survival is poorly understood, which this study sought to evaluate. Methods: A retrospective cohort study was conducted and reported following STROBE guidelines, based on adults with newly diagnosed GBM who received their first surgical intervention at Cleveland Clinic (Ohio, USA) between 2012 and 2018. Kaplan–Meier and multivariable Cox proportional hazards models were used to analyze the association between sex and MGMT promoter methylation status on overall survival (OS). MGMT was defined as methylated if the mean of CpG 1-5 ≥ 12. Propensity score matching was performed on a subset of patients to evaluate the effect of individual CpG site methylation. Results: A total of 464 patients had documented MGMT methylation status with a mean age of 63.4 (range 19–93) years. A total of 170 (36.6%) were female, and 133 (28.7%) received gross total resection as a first intervention. A total of 42.5% were MGMT methylated, with females more often having MGMT methylation than males (52.1% vs. 37.4%, p = 0.004). In univariable analysis, OS was significantly longer for MGMT promoter methylated than un-methylated groups for females (2 yr: 36.8% vs. 11.1%; median: 18.7 vs. 9.5 months; p = 0.001) but not for males (2 yr: 24.3% vs. 12.2%; median: 12.4 vs. 11.3 months; p = 0.22, p for MGMT–sex interaction = 0.02). In multivariable analysis, MGMT un-methylated versus methylated promoter females (2.07; 95% CI, 1.45–2.95; p < 0.0001) and males (1.51; 95% CI, 1.14–2.00; p = 0.004) had worse OS. Within the MGMT promoter methylated group, males had significantly worse OS than females (1.42; 95% CI: 1.01–1.99; p = 0.04). Amongst patients with data on MGMT CpG promoter site methylation values (n = 304), the median (IQR) of CpG mean methylation was 3.0% (2.0, 30.5). Females had greater mean CpG methylation than males (11.0 vs. 3.0, p < 0.002) and higher per-site CpG methylation with a significant difference at CPG 1, 2, and 4 (p < 0.008). After propensity score matching, females maintained a significant survival benefit (18.7 vs. 10.0 months, p = 0.004) compared to males (13.0 vs. 13.6 months, p = 0.76), and the pattern of difference was significant (P for CpG–sex interaction = 0.03). Conclusions: In this study, females had higher mean and individual CpG site methylation and received a greater PFS and OS benefit by MGMT methylation that was not seen in males despite equal degrees of CpG methylation.

oncology

What problem does this paper attempt to address?

The paper aims to explore the impact of gender differences, MGMT (O6-methylguanine-DNA-methyltransferase) promoter methylation status, and their interaction on the survival rates of newly diagnosed glioblastoma (GBM) patients. Specifically, the researchers aim to understand:

1. **The relationship between gender and MGMT promoter methylation**: Whether female patients exhibit MGMT promoter methylation more frequently than male patients.
2. **The impact of MGMT promoter methylation on survival rates**: Whether MGMT promoter methylation affects the overall survival (OS) and progression-free survival (PFS) of patients, and whether this impact differs between genders.
3. **Differences in methylation levels of individual CpG sites**: Whether there are significant differences in the methylation levels at various CpG sites in the MGMT promoter region between male and female patients, and whether these differences are related to survival rates.

Through this study, the authors hope to provide new insights into the clinical management and treatment strategies for glioblastoma, particularly whether different treatment approaches are needed for patients of different genders. For example, if the study results indicate that female patients derive significantly greater survival benefits from MGMT promoter methylation than male patients, this could imply that gender should be considered when selecting chemotherapy drugs.